Definium Therapeutics, Inc. (DFTX) research
Definium Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $40.32
- As of
Definium Therapeutics, Inc. (DFTX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-14.
As of . Source: SEC EDGAR filings for DFTX. Method and limitations.
Share the DFTX intelligence card
See DFTX live in the terminal
Track DFTX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live DFTX terminal, freeActive signals for DFTX
- highCONSENSUS_BUY
4 tracked funds increased DFTX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +176% to DFTX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 69% of DFTX (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 87% of DFTX (2026Q2)
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in DFTX
FREE, NO ACCOUNT
Every signal on DFTX, as it fires
You are seeing 5 of 32 signals recorded on DFTX since 2026-05-29.
The five above landed across 2 days. The other 27 were recorded on 5 other days. 25 of the 32 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in DFTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 24477V105 · 2026Q2 | $79.4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 24477V105 · 2026Q2 | $43.4M | 0.03% | , |
| Point72 Asset Management, L.P.CUSIP 24477V105 · 2026Q2 | $22.8M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 24477V105 · 2026Q2 | $14.8M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 24477V105 · 2026Q2 | $12.5M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, DFTX
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
DFTX against its peers
DFTX's return on equity of -55.3% ranks in the 20th percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | DFTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 264M | n/a | 17 |
| Operating margin | n/a | -82.9% | n/a | 16 |
| Net margin | n/a | -76.8% | n/a | 16 |
| Return on equity | -55.3% | -29.8% | 20 | 22 |
Peers (24): EWTX, ERAS, ACAD, APLS, DNTH, CRSP, IOVA, MANE, XENE, PTCT, TLX, LGND, COGT, RLAY, TVTX, ORKA, TNGX, CELC, ELVN, CNTA, MIRM, SRRK, CPRX, CGON. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (DFTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more DFTX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DFTXand get the insider, 13F, options, and confluence read in one view.